沃森生物(300142.SZ):擬終止重組手足口病疫苗(CA16型)的研發 對“上海澤潤研發費用”項目進行結項
格隆匯 8 月 14日丨沃森生物(300142.SZ)公佈,2020年8月13日,公司第四屆董事會第十二次會議審議通過了《關於發行股份購買資產並募集配套資金部分投資項目結項並將結餘募集資金永久補充流動資金的議案》。公司2016年發行股份購買資產並募集配套資金投資項目—“上海澤潤研發費用”項目共包含二價HPV疫苗III期臨牀研究、九價HPV疫苗臨牀前研究、重組手足口病疫苗(EV71型和CA16型)臨牀前研究等子項目。截至目前,二價HPV疫苗III期臨牀研究已完成,並已申報生產批件獲得國家藥品監督管理局受理;九價HPV疫苗和重組手足口病疫苗(EV71型)均已完成臨牀前研究,獲得了臨牀試驗批件或臨牀試驗通知書,已達到項目預定狀態。根據重組手足口病疫苗(CA16型)的臨牀前研究情況,經公司謹慎研究,擬終止重組手足口病疫苗(CA16型)的研發,對“上海澤潤研發費用”項目進行結項,並使用本項目結餘募集資金6613.95萬元用於永久補充流動資金。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.